Dyadic International, Inc. Appoints Joe Hazelton as Chief Business Officer
November 09, 2021 at 08:30 am EST
Share
Dyadic International, Inc. announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company?s new and existing business initiatives, including corporate strategy, business and corporate development and licensing. Mr. Hazelton will join Dyadic?s executive leadership team reporting directly to President and Chief Executive Officer, Mark Emalfarb. Mr. Hazelton brings over 20 years of pharmaceutical industry experience to Dyadic in key growth areas of product and business development, licensing, and commercialization. He joins Dyadic from Charleston Laboratories, Inc., where he has served as Chief Operating Officer and Chief Commercial Officer.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
DYADIC INTERNATIONAL, INC. 
